NCT06498973 2026-03-05
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
Clinical Trials
3 trialsNCT03113643 2025-11-04
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05233618 2025-05-28
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
University of Virginia
Phase 1 Recruiting